



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Firivumab

Cat. No.:	HY-P99620
CAS No.:	1443004-15-6
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice ^{[1][2][3]} .	
IC₅₀ & Target	IC50: 0.1-1.3 µg/mL (H1N1), 0.78 µg/mL (H2N2), 0.48-0.65 µg/mL (H5N1), 4.69 µg/mL (H6N1), 4.69 µg/mL (H6N2), 2.34 µg/mL (H8N4), 1.3 µg/mL (H8N8), 2.08 µg/mL (H9N2) and 20.83 µg/mL (H12N7) ^[1]	
In Vivo	Firivumab (CT-P22; CT120; 7.5-30 mg/kg; IP; Twenty-four hours post-infection) shows 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group ^[1] . CT-P27 (adding 7.5 mg/kg Firivumab and 7.5 mg/kg CT149) shows full protection in A/California/04/09 (H1N1)-treated mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Six- to nine-week-old female BALB/c mice with A/California/04/09 (H1N1) and A/Philippines/2/1982 (H3N2) ^[1]
	Dosage:	7.5, 15, 30 mg/kg
	Administration:	IP; Twenty-four hours post-infection
	Result:	Showed 100% protection against H1N1 virus in >15 mg/kg-treated group and 70% in 7.5 mg/kg-treated group. Could not protect mice from H3N2 infection.

REFERENCES

[1]. Kye Sook Yi, et al. Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS One. 2020 Jul 29;15(7):e0236172.

[2]. John H Beigel, et al. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463.

[3]. Seung Suh Hong, et al. Composition comprising at least two influenza a virus-neutralizing-binding molecules. EP3011968A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA